NASDAQ:CRSP CRISPR Therapeutics (CRSP) Stock Price, News & Analysis $57.33 +5.12 (+9.81%) Closing price 04:00 PM EasternExtended Trading$57.36 +0.03 (+0.06%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About CRISPR Therapeutics Stock (NASDAQ:CRSP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CRISPR Therapeutics alerts:Sign Up Key Stats Today's Range$53.12▼$59.2150-Day Range$46.54▼$60.9052-Week Range$44.12▼$78.48Volume2.99 million shsAverage Volume1.75 million shsMarket Capitalization$5.54 billionP/E RatioN/ADividend YieldN/APrice Target$68.06Consensus RatingModerate Buy Company Overview CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing gene-editing medicines using CRISPR/Cas9 technology. The company’s programs are designed to modify disease-associated genes in human cells, with the goal of treating serious conditions across hematology, oncology, autoimmune disease and regenerative medicine. Its most advanced product is Casgevy (exa-cel), an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals. Casgevy uses CRISPR/Cas9 gene editing to modify a patient’s blood stem cells and is approved in several markets for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. The product was among the first medicines based on CRISPR gene-editing technology to receive regulatory approval. Founded in 2013, CRISPR Therapeutics operates internationally, with corporate activities in Switzerland and the United States. In addition to its hemoglobinopathy program, the company is advancing investigational therapies in areas such as cancer, type 1 diabetes and immune-mediated diseases through both internal research and collaborations. Its scientific origins are associated with CRISPR pioneers Emmanuelle Charpentier and Rodger Novak, while Samarth Kulkarni has served as the company’s chief executive officer.AI Generated. May Contain Errors. Read More CRISPR Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreCRSP MarketRank™: CRISPR Therapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 519th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingCRISPR Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.61, and is based on 1 strong buy rating, 10 buy ratings, 6 hold ratings, and 1 sell rating.Upside PotentialCRISPR Therapeutics has a consensus price target of $68.06, representing about 19.8% upside from its current price of $56.80.Amount of Analyst CoverageCRISPR Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CRISPR Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CRISPR Therapeutics are expected to grow in the coming year, from ($4.47) to ($3.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CRISPR Therapeutics is -11.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CRISPR Therapeutics is -11.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCRISPR Therapeutics has a P/B Ratio of 2.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CRISPR Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.48% of the float of CRISPR Therapeutics has been sold short.Short Interest Ratio / Days to CoverCRISPR Therapeutics has a short interest ratio ("days to cover") of 10.73, which indicates bearish sentiment.Change versus previous monthShort interest in CRISPR Therapeutics has recently increased by 0.13%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCRISPR Therapeutics does not currently pay a dividend.Dividend GrowthCRISPR Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.71 News SentimentCRISPR Therapeutics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 16 news articles for CRISPR Therapeutics this week, compared to 9 articles on an average week.Search InterestOnly 10 people have searched for CRSP on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat Follows15 people have added CRISPR Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CRISPR Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.20% of the stock of CRISPR Therapeutics is held by insiders.Percentage Held by Institutions69.20% of the stock of CRISPR Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about CRISPR Therapeutics' insider trading history. Receive CRSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRSP Stock News HeadlinesWall Street Analysts Think CRISPR Therapeutics (CRSP) Is a Good Investment: Is It?September 17 at 10:50 AM | finance.yahoo.comCRISPR Therapeutics (CRSP) Gains Attention As CASGEVY Momentum Builds But Is The Valuation Too RichSeptember 16 at 12:54 PM | finance.yahoo.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.September 17 at 1:00 AM | Weiss Ratings (Ad)CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to KnowSeptember 15 at 8:16 PM | finance.yahoo.comCRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on ItSeptember 15 at 10:10 AM | finance.yahoo.comCRISPR Therapeutics AG (CRSP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14 at 7:56 PM | seekingalpha.comCRISPR Therapeutics set to snap six-session losing streakSeptember 14 at 2:55 PM | msn.comAbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?September 14 at 10:40 AM | fool.comSee More Headlines CRSP Stock Analysis - Frequently Asked Questions How have CRSP shares performed this year? CRISPR Therapeutics' stock was trading at $52.44 at the start of the year. Since then, CRSP stock has increased by 8.3% and is now trading at $56.80. How were CRISPR Therapeutics' earnings last quarter? CRISPR Therapeutics AG (NASDAQ:CRSP) issued its quarterly earnings data on Tuesday, June, 30th. The company reported ($0.94) earnings per share for the quarter. The business had revenue of $10.18 million for the quarter. CRISPR Therapeutics had a negative trailing twelve-month return on equity of 24.39% and a negative net margin of 3,368.72%. When did CRISPR Therapeutics IPO? CRISPR Therapeutics (CRSP) raised $64 million in an initial public offering on Wednesday, October 19th 2016. The company issued 4,000,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager. Who are CRISPR Therapeutics' major shareholders? Top institutional investors of CRISPR Therapeutics include California State Teachers Retirement System (0.10%), Shah Wealth Advisors LLC (0.07%), Handelsbanken Fonder AB (0.04%) and Corient Private Wealth LP (0.03%). Insiders that own company stock include Simeon George, Samarth Kulkarni, James R Kasinger, Naimish Patel, Julianne Bruno, John Greene and Raju Prasad. View institutional ownership trends. How do I buy shares of CRISPR Therapeutics? Shares of CRSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CRISPR Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CRISPR Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AUO (AUOTY) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings6/30/2026Today9/17/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 13 days, CRSP's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CRSP CIK1674416 Webwww.crisprtx.com Phone(617) 315-4600FaxN/AEmployees393Year Founded2013Price Target and Rating Average Price Target for CRISPR Therapeutics$68.06 High Price Target$110.00 Low Price Target$9.00 Potential Upside/Downside+18.7%Consensus RatingModerate Buy Rating Score (0-4)2.61 Research Coverage18 Analysts Profitability EPS (Trailing Twelve Months)($4.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$581.60 million Net Margins-3,368.72% Pretax Margin-3,346.08% Return on Equity-24.39% Return on Assets-18.25% Debt Debt-to-Equity Ratio0.34 Current Ratio17.85 Quick Ratio17.85 Sales & Book Value Annual Sales$3.51 million Price / Sales1,579.44 Cash FlowN/A Price / Cash FlowN/A Book Value$20.17 per share Price / Book2.84Miscellaneous Outstanding Shares96,690,000Free Float91,665,000Market Cap$5.54 billion OptionableOptionable Beta1.76 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:CRSP) was last updated on 9/17/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
